Genome-scale CRISPR-Cas9 knockout screening in hepatocellular carcinoma with lenvatinib resistance

Lenvatinib is the first target drug approved for advanced hepatocellular carcinoma (HCC). However, the development of drug resistance is common, and the mechanisms of lenvatinib resistance and resistant targets in HCC are poorly understood. By using CRISPR/Cas9 library screening, we screened out two...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yonggang, Shen, Haoming, Huang, Wenjie, He, Sha, Chen, Jianlin, Zhang, Di, Shen, Yongqi, Sun, Yifan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602346/
https://www.ncbi.nlm.nih.gov/pubmed/34795217
http://dx.doi.org/10.1038/s41420-021-00747-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602346/
https://www.ncbi.nlm.nih.gov/pubmed/34795217
http://dx.doi.org/10.1038/s41420-021-00747-y

Ejemplares similares